StockData

Celularity vs Jaguar Health

CELU and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CELU and JAGX compare

Celularity is the larger company, worth 9.3 times as much as Jaguar Health ($20.1M against $2.2M).

Jaguar Health grew revenue faster over the last twelve months (136% versus −58.1% for Celularity).

Celularity scores higher on the StockData Score (7 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCELUJAGX
Size and price
Market cap$20.1M$2.2M
Share price$0.619$0.420
Change, 1 year−61.1%−100.0%
Change, 5 years−99.1%−100%
Beta (5Y)1.78–
Employees11547
StockData Score
Total score7 (better)3
Valuation score11
Growth score12 (better)
Performance score1 (better)0
Health score4 (better)0
Dividend score00
Valuation
P/S1.1×0.1× (better)
Growth
Revenue growth (TTM)−58.1%136% (better)
Revenue growth, 5Y average13.2% (better)4.2%
Profitability
Gross margin19.2%82.3% (better)
Operating margin−264%−93.1% (better)
Net margin−246%–
Financial health
Interest coverage–−25.9×
Current ratio0.110.69 (better)
Altman Z-score−16.48 (better)−18.45
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.8%–
Held by insiders–17.1%
Short interest, % of float–4.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.